Core Insights - Kanghong Pharmaceutical reported a revenue of 1.17 billion yuan for Q3 2025, representing a year-on-year growth of 4.75% [2] - The net profit attributable to shareholders for Q3 2025 was 303 million yuan, showing a year-on-year increase of 7.71% [2] - For the first three quarters of 2025, the company achieved a total revenue of 3.624 billion yuan, which is a 6.23% increase compared to the same period last year [2] - The net profit attributable to shareholders for the first three quarters of 2025 reached 1.033 billion yuan, reflecting a year-on-year growth of 6.08% [2]

2022 年股票增值权激励计划第三个行权期行权条件成就的 法律意见书 二〇二五年十月 北京通商（成都）律师事务所 关于 成都康弘药业集团股份有限公司 | | | 释义 在本法律意见书中，除非文中另有说明，下列词语具有如下涵义： | 本所 | 指 | 北京通商（成都）律师事务所 | | --- | --- | --- | | 公司或康弘药业 | 指 | 成都康弘药业集团股份有限公司 | | 本激励计划 | 指 | 成都康弘药业集团股份有限公司 年股票增值权激励计划 2022 | | 《激励计划（草案）》 | 指 | 《成都康弘药业集团股份有限公司 2022 年股票增值权激励计 划（草案）》 | | 《考核办法》 | 指 | 《成都康弘药业集团股份有限公司 年股票增值权激励计 2022 | | | | 划考核实施管理办法》 | | 股票增值权 | 指 | 公司授予激励对象在一定条件下通过模拟股票市场价格变化的 方式，获得由公司支付的兑付价格与行权价格之间差额的权利 | | 激励对象 | 指 | 本激励计划中获得股票增值权的公司外籍核心员工（不包括独 立董事、监事、单独或合计持有公司 5%以上股份的股东或实 | | ...

Group 1 - The core point of the article is that Kanghong Pharmaceutical announced an adjustment to its organizational structure during its board meeting held on October 28, 2025 [1] - For the first half of 2025, Kanghong Pharmaceutical's revenue composition was 99.97% from the pharmaceutical manufacturing industry and 0.03% from other businesses [1] - As of the report, Kanghong Pharmaceutical has a market capitalization of 29.9 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [1] - A new "slow bull" market pattern is emerging, indicating a shift in market dynamics [1]

Company Performance - Kanghong Pharmaceutical reported a revenue of approximately 3.624 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.23% [1] - The net profit attributable to shareholders of the listed company was about 1.033 billion yuan, showing a year-on-year growth of 6.08% [1] - Basic earnings per share reached 1.12 yuan, which is a year-on-year increase of 5.66% [1] Market Context - As of the report, Kanghong Pharmaceutical has a market capitalization of 29.9 billion yuan [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥1,170,203,783.10, representing a 4.75% increase year-over-year[5] - Net profit attributable to shareholders was ¥303,207,431.06, up 7.71% compared to the same period last year[5] - The basic earnings per share for the period was ¥0.33, which is a 6.45% increase year-over-year[5] - Total operating revenue for the current period reached ¥3,623,865,721.06, an increase of 6.2% compared to ¥3,411,293,193.61 in the previous period[22] - Net profit for the current period was ¥1,021,124,394.93, representing a growth of 5.8% from ¥964,889,830.03 in the previous period[23] - Earnings per share (EPS) for the current period was ¥1.12, compared to ¥1.06 in the previous period, indicating an increase of 5.7%[23] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥9,870,033,859.62, reflecting a 5.65% increase from the end of the previous year[5] - Total assets increased to ¥9,870,033,859.62 from ¥9,341,936,339.67, marking a growth of 5.7%[21] - Total liabilities rose to ¥719,980,060.47, up from ¥695,069,259.77, reflecting an increase of 3.7%[21] - The total equity attributable to shareholders of the parent company was ¥9,166,361,019.00, compared to ¥8,653,202,130.15, an increase of 5.9%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,408,275,688.02, an increase of 12.26%[5] - Operating cash flow for the current period was ¥1,408,275,688.02, an increase of 12.2% compared to ¥1,254,467,611.62 in the previous period[24] - Cash inflow from sales of goods and services was ¥3,867,965,865.99, compared to ¥3,649,309,553.09 in the previous period, reflecting a growth of 6.0%[24] - Total cash outflow from operating activities was ¥2,578,063,329.64, an increase from ¥2,430,058,668.41 in the previous period[24] - Cash flow from financing activities resulted in a net outflow of -¥519,112,267.76, compared to -¥343,198,374.48 in the previous period[25] Investments and Financial Activities - Investment income from financial products was recorded at ¥11,533,310.23, classified as regular income due to its frequency and relevance to business operations[10] - The company reported a financial income of ¥41,612,234.52, down from ¥47,008,183.20, a decline of 11.4%[22] - The company reported a significant increase of 269.90% in prepayments, totaling ¥42,378,031.18[12] - Total cash inflow from investment activities was ¥3,252,470,799.99, up from ¥2,132,043,970.54 in the previous period, representing a 52.5% increase[24] - Net cash flow from investment activities was -¥2,732,633,098.12, worsening from -¥2,316,936,761.18 in the previous period[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 23,995[15] - Chengdu Kanghong Technology Industry (Group) Co., Ltd. holds 31.70% of shares, totaling 292,014,900 shares[15] - The top ten shareholders include Chengdu Kanghong Technology Industry (Group) Co., Ltd. and several individual shareholders, with no participation in margin trading reported[16] Research and Development - Research and development expenses for the current period were ¥334,157,560.21, slightly down from ¥342,158,088.75, a decrease of 2.4%[22] - The company received a drug registration certificate for Lifi Shite eye drops from the National Medical Products Administration[17] - The company’s subsidiary received clinical trial approval for KH813 injection from the National Medical Products Administration[17] - The company completed the absorption merger of its wholly-owned subsidiary Sichuan Jishengtang Pharmaceutical Co., Ltd.[17] Current Assets and Cash Management - The company reported a total current assets of ¥7,023,154,380.28, an increase from ¥6,288,819,404.18 at the beginning of the period[19] - Cash and cash equivalents decreased to ¥3,828,071,098.77 from ¥5,689,515,722.69[19] - The ending balance of cash and cash equivalents was ¥3,781,405,973.18, an increase from ¥3,263,580,439.45 in the previous period[25] - The company’s cash and cash equivalents decreased by ¥1,844,021,273.38 during the period, compared to a decrease of ¥1,406,413,781.15 in the previous period[25]

二、监事会会议审议情况 证券代码：002773 证券简称：康弘药业 公告编号：2025-058 成都康弘药业集团股份有限公司 第八届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届监 事会第十三次会议于 2025 年 10 月 28 日在公司会议室以现场和通讯 相结合的方式召开。会议通知于 2025 年 10 月 23 日以书面、传真或 电子邮件等形式向所有监事发出。本次监事会应到监事 3 名，实到监 事 3 名（其中：监事程砚梅女士以通讯方式参加），会议由监事会主 席龚文贤主持，公司董事会秘书列席会议。本次会议的召开符合《中 华人民共和国公司法》和《成都康弘药业集团股份有限公司章程》的 有关规定。 会议以书面记名投票方式通过了如下决议： 1、会议以3票同意，0票反对，0票弃权审议通过了《2025年第三 季度报告》。 经审核，监事会认为：董事会编制和审核的公司《2025年第三季 1 / 3 度报告》的程序符合法律、行政法规和中国证监会的规定，报告内容 真实 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-057 成都康弘药业集团股份有限公司 第八届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届董 事会第十三次会议于2025年10月28日在公司会议室通过现场和通讯 相结合的方式召开。会议通知已于2025年10月23日以书面、传真或电 子邮件等形式向所有董事发出。本次董事会应到董事九名，实到董事 九名（其中：董事王霖先生、独立董事周德敏先生、邓宏光先生、许 楠女士以通讯方式参加），会议由董事长柯尊洪先生主持，公司监事、 董事会秘书及高级管理人员列席了会议。本次会议的召开符合《中华 人民共和国公司法》（以下简称"《公司法》"）和《成都康弘药业 集团股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 会议以书面记名投票方式表决通过了如下决议： 1. 会议以9票赞成、0票反对、0票弃权审议通过了《2025年第三 季度报告》。 《2025 年第三季度报告》于 2025 年 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-060 成都康弘药业集团股份有限公司 1、2022 年股票增值权激励计划第三个行权期行权条件达成，本 次可行权的激励对象总计 1 人，可申请行权的股票增值权数量为 18 万份，占截至2025年9月30日公司总股本921,320,954股的0.0195%。 2、本次行权对公司总股本数量无影响，对公司基本每股收益及 净资产收益率影响较小，具体影响以经会计师事务所审计的数据为准， 本次股票增值权行权不会对公司财务状态和经营成果产生重大影响。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第八届董事会第十三次会议、第八届监事会第十三 次会议，审议通过了《关于 2022 年股票增值权激励计划第三个行权 期行权条件达成的议案》，根据公司《2022 年股票增值权激励计划(草 案）》，本次 2022 年股票增值权激励计划第三个行权期为自首次授 予日起36个月后的首个交易日起至首次授予日起48个月内的最后一 1 / 11 个交易日当日止，即本次 2022 年股票增值权激励计划第三个行权期 为 2025 年 8 月 30 日 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-056 成都康弘药业集团股份有限公司 关于注销部分募集资金专用账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 1、首次公开发行股票募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）"证监 许可[2015]1198号文"核准，成都康弘药业集团股份有限公司（以下 简称 "公司"）公开发行人民币普通股股票4,560.00万股，每股发 行价为13.62元，扣除证券公司承销费、保荐费等费用后实际募集资 金净额为人民币57,624.77万元。上述募集资金已于2015年6月23日全 部到位，经信永中和会计师事务所（特殊普通合伙）审验，并出具了 XYZH/2015CDA50084号《验资报告》。 2、公开发行可转换公司债券募集资金基本情况 经中国证监会（证监许可[2019]2572号）核准，公司公开发行了 1,630.00万张可转换公司债券，每张面值100元，发行总额163,000.00 万元，扣除证券公司承销费、保荐费等费用后实际募集资金净额为人 民币160, ...

Core Points - Kanghong Pharmaceutical (002773) reported that as of October 20, 2025, the number of shareholders is 24,892 [1]